Nevertheless, the overall incidence of infections and infectious AEs was low and acceptable in MPN patients in most clinical trials and the effects of JAK2 inhibition in reducing MPN symptoms in patients were superior to possible AEs [146,147,148]. Here, JAK2 is linked to myeloproliferative neoplasm.